Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Psoriasis significantly impacts psychological and social well-being, with high rates of depression, anxiety, and suicidal ideation among patients. Effective management requires a holistic, patient ...

Results showed 66% of patients treated with icotrokinra achieved an ss-IGA score of 0/1 and 77% achieved a sPGA-G score of 0/1, compared with 11% and 21% receiving placebo, respectively, at week 16.

Once-daily 0.3% topical roflumilast foam significantly reduced severity in patients with psoriasis of the scalp and body over 8 weeks, with a favorable safety profile. “Use of roflumilast foam ...

In 2022, a drug called deucravacitinib was approved by the U.S. Food and Drug Administration to treat psoriasis. This medication targets TYK2 in a way that stops its ability to relay harmful ...

INDIANAPOLIS (WISH) — A drug already approved by the U.S. Food and Drug Administration to treat psoriasis could offer new hope for people with Type 1 diabetes, according to a new study co-led by ...

BMS has previously said it reckons Sotyktu could become a $4 billion seller at its peak, fuelled by head-to-head studies showing it was more effective at treating moderate-to-severe psoriasis than ...

Johnson & Johnson has moved a step closer to filing a potential first-in-class therapy for psoriasis after the drug hit the mark in a phase 3 trial. Once-daily oral IL-23 inhibitor icotrokinra ...

Between 61% to 82% of patients with atopic dermatitis, psoriasis, and xerosis reported improvement in their symptoms following 4 weeks of using a ceramide-containing skin care regimen. Researchers ...

A content creator shared a touching encounter with a woman suffering from psoriasis after being judged by others. Psoriasis is a skin condition that often causes people to be unfairly judged or ...

Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days ...